Perflutren
Active ingredient
Sold as Optison · Luminity · DEFINITY
- Drug class
- -
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 4
Overview
Perflutren is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| EU European Union | EMA | 2 | May 29, 2026 |
| GB United Kingdom | MHRA | 1 | January 9, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
EUEuropean Union· EMA
2 products
Uses
This medicinal product is for diagnostic use only. OPTISON is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular endocardial border delineation with resulting improvement in wall motion visualisation.
OPTISON should only be used in patients where the study without contrast enhancement is inconclusive.
How to take
GBUnited Kingdom· MHRA
1 product
Uses
This medicinal product is for diagnostic use only. Luminity is an ultrasound contrast-enhancing agent for use in adult patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.
How to take
CACanada· Health Canada
1 product
Uses
DEFINITY (perflutren injectable suspension) is indicated for: Echocardiography:
Contrast-enhanced ultrasound imaging of cardiac structures (ventricular chambers and endocardial borders) and function (regional wall motion) in adult patients with suboptimal echocardiograms. Abdominal Ultrasound: Contrast-enhanced ultrasound imaging of the liver and kidneys in adult patients to improve the evaluation of pathology.
1 Pediatrics Pediatrics (below the age of 16): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.
Drug interactions
Known interactions involving Perflutren. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]European Medicines Agency · EMEA/H/C/000166 · revised May 29, 2026
- [2]MHRA (UK) · PLGB342580003 · revised January 9, 2026
- [3]Health Canada (DPD) · 02243173 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.